Dianthus Therapeutics, Inc. · NASDAQ:DNTH
Dianthus Therapeutics — Investor Presentation (January 2024)
25 slides from Dianthus Therapeutics's investor presentation, Jan 8, 2024
Slide 1: Corporate Presentation January 2024
Corporate Presentation January 2024 Exhibit 99.1
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS Certain statements in this presentation (“Presentation”), other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United Stated P
Slide 3: Advancing next-generation complement therapies for autoimmune disease patients
Lead program, DNTH103, is a potent investigational monoclonal antibody that targets the classical complement pathway by selectively inhibiting active C1s protein Top-line Ph. 1 data confirm a ~60-day half-life, potent classical pathway inhibition, and a potentially differentiated safety profile Cash
Slide 4: DNTH103 offers pipeline in a product potential in multiple neuromuscular indications
DNTH103 offers pipeline in a product, best-in-class potential in multiple neuromuscular indications Generalized Myasthenia Gravis Multi-billion $ market today, with opportunity for a differentiated complement inhibitor to further penetrate and expand first-line biologics use ~60,000 U.S. patients Ch
Slide 5: DNTH103 rapidly advancing into three Phase 2 trials in 2024
Program (Target) Target Population 2024 2025 DNTH103 (S.C. Active C1s antibody) Generalized Myasthenia Gravis (gMG) ~60,000 U.S. patients Multifocal Motor Neuropathy (MMN) ~5,000-10,000 U.S. patients Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) ~15,000 U.S. patients DNTH103 is rapidly ad
Slide 6: Opportunity in Myasthenia Gravis
DNTH103 Opportunity in Myasthenia Gravis
Slide 7: gMG represents a multi billion-dollar opportunity with only two approved classes
gMG represents a multi billion-dollar opportunity with only two approved classes, each with room to improve Approved in gMG, aHUS, NMOSD, PNH Soliris Ultomiris Soliris & Ultomiris >$5B in sales and growing; ~1/3 in gMG1 (only I.V.) U.S. gMG estimated patient population: ~60,000 Vyvgart I.V. sales in
Slide 8: DNTH103 target product profile is highly differentiated vs. approved biologics for gMG
DNTH103 Lower volume, less frequent, self-administered S.C. More frequent and/or higher-volume, in-clinic I.V. Need for increased convenience and reduced patient burden DNTH103 target product profile is highly differentiated vs. currently approved biologics for gMG 1 Can be self-administered daily v
Slide 9: Targeting C1s preserves lectin and alternative pathway immune activity
Membrane Attack Complex (MAC) Targeting C1s preserves critical immune activity of lectin and alternative pathways, with the aim to provide a safer therapeutic option versus terminal pathway inhibitors Complement inhibitors are well established in gMG and other severe autoimmune disorders Downstream
Slide 10: C1s is a clinically validated target in the classical complement pathway
C1q lgG antibody Cell Surface C1s is a clinically validated target in the classical complement pathway with an FDA approved therapy The C1 complex The initial component of the classical complement pathway consisting of C1q, C1r and C1s 3 2 2 3 Active C1s A serine protease that executes catalytic fun
Slide 11: DNTH103 exploits validated C1s biology with best-in-class properties
DNTH103 exploits validated C1s biology and has been designed with best-in-class properties Extended half-life Validated YTE half-life extension technology applied Clinical data demonstrates half-life of ~60 days Novel IP Provisional patent applications for composition of matter and method of use exp
Slide 12: Clinical Development
DNTH103 Clinical Development
Slide 13: DNTH103 Phase 1 healthy volunteer study design
SAD 1 (1 mg/kg) SAD 3 (30 mg/kg) SAD 2 (10 mg/kg) MAD 1 Q2W (300 mg) MAD 2 Q2W (600 mg) SAD 1 (300 mg) SAD 2 (600 mg) I.V. Administration S.C. Administration S.C. Administration SAD MAD DNTH103 Phase 1 healthy volunteer study was designed to validate extended half-life, potency and safety 44 HVs enr
Slide 14: Deep and sustained complement inhibition in healthy volunteers
DNTH103 has demonstrated deep and sustained complement inhibition in healthy volunteers DNTH103 demonstrated a ~60-day half-life and IC90 of 87 µg/mL I.V. SAD: Linear PK with Exposure Proportional Across Doses S.C. MAD: Strong Accumulation with Q2W Dosing PK/PD: Analysis Demonstrates IC90 of 87 µg/m
Slide 15: Phase 1 data confirms potent classical pathway inhibition as Q2W S.C. injection
15mg/kg I.V. on Day 0 300mg S.C. Q2W starting Day 7 DNTH103 Phase 1 data confirms potent inhibition of the classical pathway as a Q2W S.C. injection ~60-day half-life IC90 calculated at 87 µg/mL Ph. 1 Data Confirms Simulation using data from 60 healthy volunteers dosed across multiple cohorts demons
Slide 16: Generally well tolerated with favorable safety profile in Phase 1
DNTH103 was generally well tolerated, with a favorable safety profile in Phase 1 No standard safety lab findings (hematology, chemistry, coagulation LFTS and renal function) No serious adverse events No infection adverse event signal and no infections related to encapsulated bacteria Five participan
Slide 17: S.C. gMG Phase 2 trial design
DNTH103 S.C. gMG Phase 2 trial design A global, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, and PK / PD of DNTH103 administered S.C following initial loading dose 12-Week S.C. Treatment Screen: Day -42 to -1 Open-Label Extension: 52 Weeks DNTH103
Slide 18: CIDP: neuromuscular indication with high unmet medical need
Neuromuscular indication with high unmet medical need Evidence supports Classical Complement role in disease CIDP is an attractive commercial opportunity with clinical PoC demonstrated by an active-C1s inhibitor DNTH103, a low-volume Q2W S.C., Phase 2 trial for CIDP planned for initiation in 2H’24 ~
Slide 19: MMN: neuromuscular indication with high unmet medical need
Neuromuscular indication with high unmet medical need Evidence supports Classical Complement role in disease MMN is a classical pathway driven disease with no approved targeted biologic therapies DNTH103, a low-volume Q2W S.C., Phase 2 trial for MMN planned for initiation in Q2’24 No approved target
Slide 20: Corporate
Corporate
Slide 21: Strategy to initiate multiple Phase 2 trials in 2024
Strategy to initiate multiple Phase 2 trials in 2024 ahead of transformative Phase 2 gMG readout 2024 2025 DNTH103 (S.C. Active C1s) gMG MMN CIDP Key External Catalysts Key External Catalysts Strong balance sheet with ~$173M1 of cash as of 12/31 and runway into the second quarter of 2026 Q1 Initiate
Slide 22: Accomplished team of biotech industry veterans and scientists
Accomplished team of biotech industry veterans and scientists committed to bringing innovation to market Select Auto-Immune Drugs Developed by Dianthus Team Select Experience Includes: Marino Garcia President & CEO Simrat Randhawa, M.D. Chief Medical Officer Ryan Savitz Chief Financial Officer Adam
Slide 23: Appendix
Appendix
Slide 24: Improves neurotransmission and muscle contraction in an AChR+ MG model
DNTH103 improves neurotransmission and muscle contraction in an AChR+ MG model Results provide further scientific rationale for DNTH103 in gMG Serum from MG patients used in a validated in vitro MG model1,2,3 Assessed improvement in neurotransmission and muscle contraction of ravulizumab* and DNTH10
Slide 25: In vitro study demonstrates lower risk of Neisseria meningitidis infections
DNTH103 in vitro study demonstrates lower risk of Neisseria meningitidis infections Anti-capsular antibody (Anti -Nm) mimics N. meningitidis vaccination 0 50 100 150 % Bacterial Survival Serum +Anti - Nm 0.3 uM 1.0 uM DNTH103 Anti - C5 No treatment Results further validate the differentiated safety
Dianthus Therapeutics — Investor Presentation (January 2024) on 6ix